11. 重症筋無力症 [臨床試験数:226,薬物数:172(DrugBank:45),標的遺伝子数:43,標的パスウェイ数:118

Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-IPR-150060812014-07-182015-03-14A prospective study of combined use of prednisone and methotrexate for the treatment of myasthenia gravisA prospective study of combined use of prednisone and methotrexate for the treatment of myasthenia gravis myasthenia gravisprednisone group:prednisone;Prednisone + methotrexate:Prednisone + methotrexate;Xuan Wu Hospital, Capital Medical UniversityNULLRecruiting1880Bothprednisone group:15;Prednisone + methotrexate:15;NULL
2NCT00814138April 200923/12/2008Efficacy of Methotrexate in Myasthenia GravisPhase II Trial of Methotrexate in Myasthenia GravisMyasthenia GravisDrug: Methotrexate;Other: PlaceboUniversity of Kansas Medical CenterNULLCompleted18 YearsN/AAll50Phase 2United States;Canada
3EUCTR2007-001377-28-PT09/01/200925/08/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
4EUCTR2007-001377-28-DE01/09/200815/05/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
5EUCTR2007-001377-28-NL15/07/200829/05/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2007-001377-28-AT26/06/200827/05/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
7EUCTR2007-001377-28-FR11/06/200829/02/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria